Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-HYNIC-PEG liposome is a **radiolabeled PEGylated liposome** in which the liposome membrane incorporates a hydrazino-nicotinyl (HYNIC) derivative as a chelator, enabling rapid and stable labeling with the gamma-emitting radionuclide technetium-99m (99mTc)[1][3]. The addition of a polyethylene glycol (PEG) layer increases circulation time and reduces uptake by the reticuloendothelial system. This compound is primarily developed as a **radiopharmaceutical for SPECT imaging**, particularly to track the in vivo distribution and localization of liposomal drug formulations and as an infection imaging agent. The 99mTc-HYNIC labeling method offers higher efficiency and stability than prior methods, facilitating clinical workflow and enhancing image quality[1][3]. PEGylated formulations exhibit improved tumor or infection site localization via the enhanced permeability and retention effect, making them valuable for noninvasive monitoring of drug delivery and disease localization.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-HYNIC-PEG liposome.